October 2021 OSE Immunotherapeutics Announces Appointment of Gérard Tardy as Chairman of Company’s Board of Directors
October 2021 O SE Immunotherapeutics Present ing at the 23rd Annual International Partnering Conference BIO EUROPE®
October 2021 OSE Immunotherapeutics Signs a License Option Agreement with Inserm to Develop a New Cancer Immunotherapy
October 2021 Selexis SA and OSE Immunotherapeutics Expand Strategic Alliance to Further Advance OSE’s OSE-172 and OSE-703